|
WO2018099539A1
|
|
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
WO2017167350A1
|
|
Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
|
|
WO2016019969A1
|
|
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
|
US2014286999A1
|
|
Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
|
|
US2015037278A1
|
|
Initial relative lymphocyte count as predictive biomarker
|
|
US2006115481A1
|
|
Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
|
|
DE10043437A1
|
|
Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites
|
|
WO0018435A1
|
|
Time-staggered utilization of tumor cells in combination with intact antibodies for immunization
|
|
WO0018806A1
|
|
Bispecific and trispecific antibodies which specifically react with inducible surface antigens as operational target structures
|
|
DE19859115A1
|
|
Use of delayed tumor cells in combination with intact antibodies for immunization
|
